Australia has one of the highest incidence rates of mesothelioma in the world.

Mesothelioma is a form of cancer that most often affects the thin linings of the organs in the chest (pleura) and abdomen (peritoneum). Mesothelioma is closely linked with asbestos exposure either at work or among family members of workers and people living in neighbourhoods near asbestos factories and mines. The risk is lifelong.

TOGA, the Thoracic Oncology Group of Australasia, is working to positively change the outcome for patients with mesothelioma through an innovative clinical trials program and by providing medical education & awareness.

In this Podcast, we talk with Professor Anna Nowak, Pro Vice Chancellor at UWA, Medical Oncologist and Director of the National Centre for Asbestos Related Diseases and Medical Oncologist Dr Steven Kao from the Chris O’Brien Lifehouse with a special interest in predictive and prognostic factors in mesothelioma, about emerging treatments for mesothelioma patients and the DREAM3R trial.

In a successful partnership spanning US, Australia and New Zealand, TOGA investigators are collaborating with PrECOG and NHMRC CTC and have opened a Phase III trial called DREAM3R investigating the addition of immunotherapy to chemotherapy in patients with newly diagnosed malignant pleural mesothelioma. Australia has one of the highest incidence rates of mesothelioma in the world, and new promising therapies are desperately needed. The DREAM3R trial follows on from the exciting Phase II clinical trial results in PrECOG’s PrE0505 trial https://rb.gy/q44it3 and the Australian DREAM trial https://rb.gy/lrkhvo that both showed early promising results with the chemotherapy and durvalumab combination. More information on the DREAM3R trial can be found here: https://rb.gy/2h9f5v and https://rb.gy/rkznyt’

Further trial information available here:

https://rb.gy/2h9f5v and https://rb.gy/rkznyt